LabConnect has received a healthy $24.5 million in its first equity investment.

Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.

Charles River Laboratories has beefed up its library of patient-derived xenografts (PDXs) by adding new genetic characteristics into the mix.

DelMar is advancing its first-in-class brain cancer med dianhydrogalactitol (VAL-083) into phase 3, and it has recruited PRA Health Sciences to conduct that…

Quintiles and IMS Health came together last year in a massive $19 billion megamerger, and now INC and inVentiv are looking to follow suit, combining into one…

Not a week seems to go by without a CRO sale rumor, and now the Wall Street Journal is adding Parexel to that list.

Asia-Pacific CRO George Clinical has topped up its cancer services and boosted its U.S. presence after acquiring Memphis, Tennessee-based Vector Oncology'…

After raising $31 million just last year, California-based clinical research company Science 37 has now served up a Series C round worth $29 million.

R&D